

10/075,918

- 8 -

Barvian et al.

REMARKS**Claim Status**

Claims 3, 6, 7, 18, 19 and 21-23 are pending in the application.

Claims 3, 6, 7 and 18 have been amended.

Claim 20 has been cancelled.

Objection to the Specification

Formula III on page 4 has been objected to because of the use of the symbol "-" in R^4R^5-N and $N-R^4R^5$. The paragraph containing Formula III has been amended to use the more common representations R^4R^5N and NR^4R^5 as suggested.

Objection to Claim 7

Claim 7 has been objected to as allegedly containing some duplicate and triplicate chemical names. Claim 7 has been amended to delete any multiple occurrences of chemical names.

35 U.S.C. § 112, First Paragraph

Claims 3, 6 and 20 have been rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. Applicants note that the first paragraph of this rejection mentions the written description requirement, but that the remainder of the rejection is concerned with enablement. Thus, applicants believe that this rejection was intended to be an enablement rejection and have addressed it as such. The rejection is concerned specifically with the treatment of breast cancer.

In order to expedite allowance of this application, claims 3 and 6 have been amended to delete breast cancer, and claim 20 has been canceled.

10/075,918

- 9 -

Barvian et al.

35 U.S.C. §112, Second Paragraph


Claims 3 and 18-23 have been rejected under 35 U.S.C. § 112, second paragraph, because the use of the symbol "-" in R^4R^5-N and $N-R^4R^5$ is allegedly unclear. Claims 3 and 18 have been amended to use the more common representations R^4R^5N and NR^4R^5 . Claim 19 and 21-23 depend of claim 18, which has been amended. Claim 20 has been canceled.

In view of the amendments and remarks made above, Applicants believe that claims 3, 6, 7, 18, 19 and 21-23 are in condition for allowance. Reconsideration and allowance of claims 3, 6, 7, 18, 19 and 21-23 is respectfully requested.

Date:

4/6/2005

Respectfully submitted,



Todd M. Crissey

Reg. No. 37,807

Pfizer, Inc.

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-7813

Fax (734) 622-1553